The Latest Breaking News from Cellectis

As of Oct. 16, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Three emerging biotech companies — Elicio Therapeutics, Cellectis, and Autolus Therapeutics — are attracting “Strong Buy” analyst ratings in 2025 as major clinical, regulatory, and commercial catalysts position them for standout growth in the cancer treatment market.

About 14 months after inking a natural killer cell deal with Cellectis SA (NASDAQ:CLLS), Cytovia plans to list on NASDAQ via a merger with the SPAC Isleworth Healthcare Acquisition Corp (NASDAQ:ISLE). The company went on to create a China joint venture. The biotech teamed up with China-based biotech investor TF Capital to form CytoLynx Therapeutics with…

Cellectis SA (NASDAQ:CLLS) released preclinical data on its product candidate UCART20x22 at the American Association for Cancer Research (AACR) Annual Meeting.  The Company said that the data showed preclinical proof of concept with the potential to overcome common mechanisms of resistance to CAR T-cell therapies in relapsed or refractory Non-Hodgkin Lymphoma (r/r NHL),…

Cellectis (NASDAQ:CLLS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cellectis beat estimated earnings by 47.83%, reporting an EPS of $-0.48 versus an estimate of $-0.92.

Cellectis (NASDAQ:CLLS) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate that Cellectis will report an earnings per share (EPS) of $-0.92.